Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Transcom Holding AB (publ): Year-end-report 2021

Fourth quarter 2021 highlights · Revenue increased to 175.3M€ (157.4) · EBITDA excluding non-recurring items* increased to 26.2M€ (23.7) · EBITDA margin excluding non-recurring items amounted to 14.9% (15.1%) · Operating cash flow amounted to 4.3M€ (8.5) · Net debt/EBITDA* amounted to 4.1 (3.3) January-December 2021 · Revenue increased to 623.1M€ (557.8) · EBITDA excluding non-recurring items* increased to 74.8M€ (70.8) · EBITDA margin excluding non-recurring items amounted to 12.0% (12.7%) · Operating cash flow amounted to 22.0M€ (50.3) Comments by the

Interim Report Fourth Quarter and Annual Financial Statement Release 2021

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 31.12.2021. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”In Q4 and 2021 in general our endurance was tested once again in terms of commercial traction. On the other hand, we experienced solid progress on all other fronts: · International sales are

LeadDesk continues growing with two acquisitions and new enterprise customers

LeadDesk Plc press release 24 February 2022, 9:10Unofficial translation of company release 24 February 2022, 9:00 am. In case the document differs from the original, the Finnish version prevails. LeadDesk Plc FINANCIAL STATEMENTS 1/1–31/12/2021 Figures in parenthesis refer to the equivalent period in the previous year, unless otherwise stated. Figures presented in this press release are unaudited.  July-December 2021 · Revenue EUR 12,545 (7,588) thousand, growth 65.3% · Comparable pro forma revenue* EUR 14,110 (12,339*) thousand, growth 14.4% · Annual recurring revenue

Year-end Report January – December 2021

lmportant commercial progress · New CEO appointed. · First commercial hydrogen project. · Air Quality sensor integrated in AAC's customer offer. Outcome October-December · Net sales amounted to 680 (23) kSEK. · Profit after net financial items amounted to -3,041 (-4,494) kSEK. · Basic and diluted earnings per share: -0,23 (-0,41) SEK. · Cash flow from operating activities and investing activities: -1,360 (-2,207) kSEK. Outcome January-December · Net sales amounted to 2,335 (1,177) kSEK. · Profit after net financial items amounted to -11,620 (-12,795)

Alzinova AB Year end report 2021

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year end report for the period January - December 2021Twelve months, January – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -7,552,006 SEK (-6,499,557 SEK). · Earnings per share amounted to -0.48 SEK (-0.41 SEK). · Equity ratio amounted to 96.5% (95.2%). Three months, October – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,455,624 SEK (-2,361,085 SEK). · Earnings per share

Asarina Pharma AB (publ) Year-end Report 2021 released

Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in our search to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.”FINANCIAL HIGHLIGHTS · Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20) · Cash balance at 31 December 2021

Fourth quarter report Q4-2021 - preparing for the pivotal trial

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 October – 31 December 2021. The fourth quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The company is progressing with planned activities: Recruitment of trial 0206 is progressing (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and we are currently finalising the preparation for the initiation of our pivotal trial with CT001 (0205). We anticipate the results from

Bricknode year-end report 2021

Highlights 2021 · Successful IPO completed with first day of trading on 9 November 2021 · Net revenue increased by 33% to 15,385 (11,578) TSEK · Net revenue retention rate: 115% · Agreement signed with a large international investment bank · First family office customer onboarded · Two new FinTech companies onboarded to the platform · Key recruitments achieved to support development and growth Comments from the CEOs, Stefan Willebrand & Erik Hagelin: “Our customer base is growing, and it is a true pleasure to see international investment banks, robo-advisors,

Year-end Report January-December 2021

• Income increased to SEK 2,805 million (894). • Net operating income increased to SEK 1,894 million (668). • Profit from property management increased to SEK 1,178 million (420). • Net letting amounted to SEK 129 million, of which SEK 98 million in the fourth quarter. • Investments in new constructions, extensions and refurbishments amounted to SEK 1,771 million. Project development, including development of building rights, contributed with increases in value of properties of SEK 661 million. The total changes in value of properties amounted to SEK 3,432 million (759). •

Elos Medtech - Year-end Report, 1 January - 31 December, 2021

October - December 2021 · Net sales for the fourth quarter amounted to SEK 184.2 (154.8) million, an increase of 19.0 percent compared to the same quarter last year. Net sales in local currencies increased by 17.7 percent. · Operating profit was SEK 25.3 (18.9) million, corresponding to an operating margin of 13.7 (12.2) percent. · Profit after financial items amounted to SEK 24.8 (13.3) million. Net financial items were positively affected by exchange rate differences of SEK 1.2 (-3.5) million and totaled SEK -0.5 (-5.6) million. · Profit after tax amounted to SEK 19.5 (11.1)

We welcome Breitling to Bibliotekstan

In the spring of 2022, luxury watch brand Breitling will open a 200 sqm boutique on Biblioteksgatan 7 in Bibliotekstan. Breitling is one of the world’s most prestigious watch brands with premium timepieces of exceptional quality and outstanding performance.Breitling was founded in Switzerland in 1884 by watchmaker Léon Breitling. Through his watchmaking business, Léon invented the analogue timer, which was used extensively by athletes and air forces. In 1915, Breitling specialised in manufacturing wristwatches, which laid the foundations for the long-established watch company that today is

Everysport Media Group (publ) publishes Year-End Report 2021: Continued strong growth focus

”The Group's net sales in the fourth quarter reached the highest figure in an individual quarter ever.” From Hannes Andersson’s CEO statement Summary of the fourth quarter 2021 • Net sales*: 59,5 mkr (23,7 mkr) • EBITDA: 8,3 mkr (2,7 mkr) • EBIT: -2,5 mkr (1,6 mkr) • Profit after tax: -6,2 mkr (2,9 mkr) • Earnings per share: -0,93 (0,63) * including acquired sales through Trav og Galoppnyt SEK 6,1million and Every Padel SEK 23,8 million Summary January - December 2021 • Net sales*: 186,8 mkr (82,3 mkr) • EBITDA: 32,6 mkr (4,8 mkr) • EBIT: 2,2 mkr (0,9 mkr)

Ranplan Group AB – Annual Statement 2021

2022-02-24 08:00 The period in summary Second half of 2021 (second half of 2020) · Total income amounted to SEK 14.9 million (13.2 million)[1] · Net sales amounted to SEK 7.0 million (5.0 million) · Operating income amounted to SEK -12.3 million (-15.2 million) · Net income amounted to SEK -13.3 million (-16.4 million) · Earnings per share amounted to SEK -0.49 (-0.75) · Cash at the end of the period amounted to SEK 17.4 million (2.6 million) Full year of 2021 (Full year of 2020) · Total income amounted to SEK 32.3 million (25.1 million)[1] · Net sales

Prostatype Genomics presents Quarterly- & Year End Report

Prostatype Genomics AB has today published its quarterly report for the fourth quarter comprising the period from 1 October 2021 to 31 December 2021, and the year end report for the financial year 2021. The report is available on the company website.Quarter 4 (1 October – 31 December 2021) summarized · Net sales amounted to 0 (347) TSEK. · EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -5 712 (-4 731) TSEK. · Cash flow from current operations in the quarter amounted -5 381 (-3 919) TSEK. · Total cash flow for the period amounted to -6 216 (

Platzer’s Annual Report 2021

Platzer’s Annual Report in Swedish is now published. The English version will be available on our website on March 21, 2022. The Annual General Meeting of Platzer Fastigheter Holding AB (publ) will take place on Wednesday, March 23, 2022. Platzer Fastigheter Holding AB (publ) For further information please contact:P-G Persson, CEO, Platzer, tel:  +46(0)734-11 12 22Fredrik Sjudin, CFO, Platzer, tel: +46(0)721-27 77 78 This information is information that Platzer Fastigheter Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was

Isofol Medical AB (publ) publishes year-end report, January - December 2021

GOTHENBURG, Sweden, February 24, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January – December 2021 is now available on the company's website, www.isofolmedical.com .Fourth quarter, October –December 2021 · Net revenue amounted to TSEK 4,704 (18,680) and other revenue to TSEK 0 (18) · The result for the period amounted to TSEK -61,170 (-54,659) · Earnings per share amounted to SEK -0.38 (-0.66) · Cash and cash equivalents on December 31 amounted to

The exercise period for warrants of series TO 1 begins today

Today, 24 February 2022, the exercise period begins for the warrants of series TO 1 that were issued in connection with Polymer Factory Sweden AB's (“Polymer Factory” or “the Company”) issue of units in April 2021. The exercise period lasts until March 17, 2022. Upon full exercise of warrants, the Company can receive a maximum of approximately SEK 5.2 million before issue costs.Information about warrants of series TO 1 In April 2021, Polymer Factory carried out an issue of units (shares and attached free of charge warrants) prior to listing on the Spotlight Stock Market. The issue of

Devyser Diagnostics AB publishes Year End Report for the period January to December 2021

Another record quarter "Devyser’s sales were also strong in the fourth quarter 2021, as well as in the other quarters of the year. We have continued to feel the impact of the pandemic, however, with new lockdowns in some countries during the quarter, particularly in Asia. We are therefore pleased to have maintained a good level of growth despite this. In the fourth quarter of the year, sales grew by 38 percent compared with the same period last year. Adjusted for exchange rate fluctuations, net sales increased by 40 percent.” Fredrik Alpsten, CEO Fourth quarter, October to December

Polygiene AB (publ.) Year-end report 2021

New financial targets and acquisitions process close out the yearQ4 in brief (October - December 2021) · Net sales amounted to MSEK 40.2 (26.6), a positive growth by 51 % · The operating profit/loss EBIT amounted to MSEK 3.9 (-2.4), an increase by 263 % · The gross margin amounted to 67.8 (64.9) % · The cash flow amounted to MSEK 2.7 (-3.1) Events during the quarter (October - December 2021) · Tricorp, leading workwear brand in the Netherlands launches products treated with Polygiene®, in which pre- and post-consumer waste is used · The reference Brazilian surf wear

Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List

· ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 · ZUBSOLV® market access improves in the public segment to 48 percent unrestricted access from 42 percent currently · ZUBSOLV® maintains unrestricted access to over 98 percent of patients in commercial segment Uppsala, Sweden – February 24, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This news follows the publication

Notice to the Annual General Meeting of Nordea Bank Abp

Nordea Bank AbpStock exchange release – Notice to general meeting24 February 2022 at 09.00 EET The shareholders of Nordea Bank Abp (the “Company”) are hereby summoned to the Annual General Meeting to be held on Thursday 24 March 2022 at 14.00 EET at the headquarters of Nordea, Hamnbanegatan 5, Helsinki, Finland. Shareholders and their proxy representatives can only participate in the Annual General Meeting and exercise shareholders’ rights by voting in advance and by making counterproposals and asking questions in advance. Instructions to shareholders are further described in Section

Nightingale Health Group’s Half-year report 1 July 2021 – 31 December 2021: Progressing faster than expected in line with strategy

Nightingale Health Plc Half-year report 1 July 2021 – 31 December 2021 (unaudited) Nightingale Health Group’s Half-year report: Progressing faster than expected in line with strategy Company Release, 24 February 2022 at 9:00 a.m. (EET) This release is a summary of Nightingale Health Plc's Half-year report from period 1 July 2021 – 31 December 2021. The full Half-year report is attached to this release. Numbers presented in brackets refer to corresponding year-on-year period unless otherwise stated. July–December 2021 key financials · Revenue was EUR 1.32 (1.01) million

Betolar and Belgian Tubobel sign a commercial agreement for a cement alternative Geoprime®

Betolar PlcCompany Announcement, inside information24 February 2022 at 8:47 A.M. EET Betolar and Belgian Tubobel sign a commercial agreement for a cement alternative Geoprime® Betolar Plc and the Belgian concrete company Tubobel Group enter into a commercial partnership to start production of low-carbon concrete products. The agreement with Betolar is valid until 2030. Tubobel, which manufactures concrete products for industry and road construction, starts manufacturing concrete pipes with Betolar's Geoprime® concept. Tubobel is the market leader in the manufacture of sewer pipes

Spinnova Plc’s Financial Statements Bulletin January–December 2021: Scaling accelerates and first technology sales materialise

SPINNOVA PLCCOMPANY RELEASE24 FEBRUARY, 2022 AT 8.45 A.M. EETSpinnova Plc’s Financial Statements Bulletin January–December 2021: Scaling accelerates and first technology sales materialise This release is a summary of Spinnova’s Financial Statements Bulletin for January to December 2021. The complete report is attached to this release and also available on the company’s website at https://spinnovagroup.com/reports/.January to December 2021 (Audited) · Revenue grew to EUR 6 063 thousand (EUR 254 thousand). · Operating loss for the period was EUR 7 172 thousand (EUR 5 473

There are no items matching the current filter
There are no more items matching the current filter
Back to top